Harmony Biosciences Holdings, Inc. (HRMY) P/E Ratio History
UndervaluedTrading at 14.1x vs 5Y avg 34.1x · 45th percentile · Below historical baseline · Data 2021–2026
Loading P/E history...
P/E Ratio Analysis
As of July 8, 2026, Harmony Biosciences Holdings, Inc. (HRMY) trades at a price-to-earnings ratio of 14.1x, with a stock price of $38.26 and trailing twelve-month earnings per share of $2.48.
The current P/E is 59% below its 5-year average of 34.1x. Over the past five years, HRMY's P/E has ranged from a low of 8.7x to a high of 195.3x, placing the current valuation at the 45th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.4x, HRMY trades at a 40% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 198.8x.
Relative to the broader market, HRMY trades at a notable discount to the S&P 500 median P/E of 25.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HRMY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HRMY Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
HRMY P/E vs Peers
Commercial Rare Disease Biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $3B | 83.4 | - | +194% | |
| $2B | 6.7Lowest | 0.65Best | +817%Best | |
| $7B | 11.5 | - | +264% | |
| $4B | 11.4 | - | +68% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
HRMY Historical P/E Data (2021–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $28.01 | $2.48 | 11.3x | -67% |
| FY2025 Q4 | Dec 31 2025 | $37.42 | $2.71 | 13.8x | -60% |
| FY2025 Q3 | - | $27.56 | $3.18 | 8.7x | -75% |
| FY2025 Q2 | Jun 30 2025 | $31.60 | $3.10 | 10.2x | -70% |
| FY2025 Q1 | Mar 31 2025 | $33.19 | $2.62 | 12.7x | -63% |
| FY2024 Q4 | - | $34.41 | $2.51 | 13.7x | -60% |
| FY2024 Q3 | Sep 30 2024 | $40.00 | $2.11 | 19.0x | -44% |
| FY2024 Q2 | Jun 30 2024 | $30.17 | $1.95 | 15.5x | -55% |
| FY2024 Q1 | Mar 31 2024 | $33.58 | $2.31 | 14.5x | -57% |
| FY2023 Q4 | Dec 31 2023 | $32.30 | $2.12 | 15.2x | -55% |
| FY2023 Q3 | Sep 30 2023 | $32.77 | $2.46 | 13.3x | -61% |
| FY2023 Q2 | Jun 30 2023 | $35.19 | $3.27 | 10.8x | -68% |
| FY2023 Q1 | Mar 31 2023 | $32.65 | $3.10 | 10.5x | -69% |
| FY2022 Q4 | Dec 31 2022 | $55.10 | $2.97 | 18.6x | -46% |
| FY2022 Q3 | Sep 30 2022 | $44.29 | $2.56 | 17.3x | -49% |
| FY2022 Q2 | - | $48.77 | $0.95 | 51.3x | +51% |
| FY2022 Q1 | - | $48.65 | $0.80 | 60.8x | +78% |
| FY2021 Q4 | Dec 31 2021 | $42.64 | $0.58 | 73.5x | +116% |
| FY2021 Q3 | - | $38.33 | $0.20 | 195.3x | +473% |
| FY2021 Q2 | Jun 30 2021 | $28.23 | $0.29 | 96.0x | +181% |
Average P/E for displayed period: 34.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HRMY — Frequently Asked Questions
Quick answers to the most common questions about buying HRMY stock.
What is HRMY's P/E ratio?
Harmony Biosciences Holdings, Inc. (HRMY) trailing twelve-month P/E ratio is 14.1x, based on TTM diluted EPS of $2.48. The 5-year average P/E is 34.1x and the historical range spans 8.7x to 195.3x.
Is HRMY stock overvalued or undervalued?
HRMY trades at 14.1x P/E, below its 5-year average of 34.1x. At the 45th percentile of its historical range (8.7x–195.3x), the stock is priced at a discount to its own history.
Is HRMY stock expensive?
No, HRMY is not expensive on a historical basis. The current P/E of 14.1x is below the 5-year average of 34.1x and sits at the 45th percentile of its valuation range.
What is HRMY's historical P/E range?
Over the past 5 years, HRMY's P/E ratio has ranged from 8.7x to 195.3x, with a median of 15.2x and an average of 34.1x. The current P/E of 14.1x places the stock at the 45th percentile of this range. Full historical data spans 2021–2026.
How does HRMY's P/E compare to the S&P 500?
HRMY trades at 14.1x P/E versus the S&P 500 median of 25.9x. The 46% discount to the market suggests lower growth expectations or perceived higher risk.
How does HRMY's valuation compare to Healthcare peers?
Harmony Biosciences Holdings, Inc. P/E of 14.1x compares to the Healthcare sector median of 23.4x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is HRMY's PEG ratio?
HRMY PEG ratio is N/A, based on a P/E of 14.1x and EPS growth of 8.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is HRMY's earnings yield?
HRMY earnings yield is 7.08%, the inverse of its 14.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.